Scientists have discovered that an artificial intelligence program, coupled with the chemical analysis of blood samples, could speed up brain tumor diagnosis.
A blood test that measures the amount of cfDNA has been indicated to be correlated with how patients will progress following a glioblastoma diagnosis.
High-grade gliomas may be able to wire themselves into the healthy brain, receiving and interpreting electrical signals from normal neurons.
A blood test for glioblastoma may be on the horizons, as researchers identify novel biomarkers that could be used for diagnosis.
A Phase I clinical trial presents veledimex – a drug-inducible gene therapy approach – as a promising treatment technique for glioblastoma.
Androgen deprivation therapy has been associated with a higher likelihood of developing dementia in men with prostate cancer when compared with individuals who are not exposed to the treatment.
A 65-year follow-up study of approximately 7000 multiple sclerosis patients has uncovered that overall, patients are 14% more likely to develop cancer compared to individuals without the disease.
Enrollment in all ongoing Depatux-M studies has been halted for newly diagnosed glioblastoma due to lack of survival benefit.
Researchers have reported that individuals undergoing CAR T-cell therapy for blood cancers are at risk of neurological side effects; categorizing and understanding these side effects could be important in future diagnosis and treatment.
We had the pleasure of speaking with Manmeet Ahluwalia about current vaccine options for glioblastoma, including a survivin vaccine (SurVaxM) for newly diagnosed glioblastoma.